Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions

TACOMA, Wash., Nov. 18, 2013 /PRNewswire/ -- Revalesio presented an update on the cellular protective effects of RNS60 in a pig model of acute myocardial infarction (AMI, heart attacks) at the 2013 American Heart Association Scientific Sessions in Dallas, Texas. As reported earlier this year at the American College of Cardiology meeting in San Francisco, RNS60 provided a 30% reduction in infarct size compared to normal saline in a model of AMI, the leading cause of death in the developed world. Despite many years of research and investigational studies, no drug has been developed to protect or limit the damage to the heart muscle caused by heart attacks. RNS60 was administered by intra-coronary injection and peripheral intravenous infusion. In this update, Revalesio researchers looked at intracellular pathways involved in cell death and survival and found that RNS60 treatment significantly modulates the level of a protein called HSP90, one of the general stress response proteins found in all cell types.

"After the initial observation of the significant improvement in infarct size achieved by RNS60 treatment, we are now diving deep into the mechanism of action behind this effect," said Revalesio's Andreas Kalmes, Ph.D., who presented the data. "The data presented at this meeting show that RNS60 inhibits apoptosis, or programmed cell death, in heart muscle cells, and provides an important clue that RNS60 affects the general stress response of cells. Apoptosis has been recognized as an important driver in heart muscle damage following a heart attack, and as a promising target to improve outcome for patients. These findings further validate our approach to develop RNS60 as a therapeutic for heart attack patients."

The reduction in infarct size, suppression of programmed cell death as a consequence of a heart attack, and the excellent safety profile provides strong rationale for the development of RNS60 as a novel treatment option for patients with AMI.

About RNS60
Revalesio has pioneered the use of RNS60 as a therapeutic that alters whole cell conductance through effects on voltage-gated ion channels and other voltage-sensing proteins, thereby modulating the activity of G protein-coupled receptors and the secretion of cytokines resulting in decreased inflammation and cell death. RNS60 contains CSN that are created by subjecting normal saline to Taylor-Couette-Poiseuille (TCP) flow. RNS60 has demonstrated a reduction in inflammatory responses that are linked to numerous diseases, including neurodegenerative, respiratory and cardiovascular diseases.

About Revalesio Corporation
Revalesio is a pioneering clinical stage biotechnology company dedicated to restoring hope and transforming lives. Founded in 2000 and based in Tacoma, Washington, Revalesio has partnered with leaders in biomedical research around the world to develop RNS60. Revalesio has an extensive patent portfolio on a novel class of anti-inflammatory products and is advancing the use of CSN in neuroinflammatory, respiratory, cardiovascular and other inflammatory diseases. For more information about Revalesio, visit revalesio.com.

Press Contact:
Jesse Thomas
253-926-5567
Email

Read more news from Revalesio Corporation

SOURCE Revalesio